Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.
The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.
The regulator said Viatris breached restrictions imposed on it during an investigation by "implementing changes to key members of its UK management team" without consent and failing to notify authorities of the breach.
Viatris did not immediately reply to MT Newswires' request for comment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。